+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 55Years
All Genders
ID06687733

Study Evaluating Intravenous NGGT002 Gene Therapy in Adults with Phenylketonuria

Led by NGGT (Suzhou) Biotechnology Co., Ltd. · Updated on 2026-08-13

18

Participants Needed

2

Research Sites

147 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effects of NGGT002, a gene therapy treatment, in adults with classic Phenylketonuria PKU, a condition caused by severe deficiency of the PAH enzyme. This Phase 12 study involves multiple centers and focuses on adults aged 18 to 55 years who carry specific genetic variants causing PKU. The trial aims to understand how well NGGT002 works and its safety when given as a single dose. Participants receive one intravenous infusion of NGGT002, which uses a viral vector to deliver a functional PAH gene. The study includes three groups receiving different dose levels, with 6 to 18 patients enrolled across these groups. After treatment, participants are followed for safety and effectiveness over a period of five years to monitor long-term outcomes. During the study, participants will have blood tests to measure plasma phenylalanine Phe levels at various points up to one year, and their diet and quality of life will be assessed. Researchers will track any side effects and changes in Phe concentrations, as well as dietary intake and PKU-related quality of life scores. Regular monitoring will support understanding of both safety and treatment impact over the long term.

CONDITIONS

Brief Title

Safety and Efficacy Study of NGGT002 in Adult Patients With Phenylketonuria

Research Team

H

Huan Zhou, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here